123I-mIBG scintigraphy in patients with known or suspected neuroblastoma

Results from a prospective multicenter trial

Terry Vik, Thomas Pfluger, Richard Kadota, Victoria Castel, Mark Tulchinsky, J. C Alonso Farto, Sherif Heiba, Aldo Serafini, Sabah Tumeh, Natalie Khutoryansky, Arnold F. Jacobson

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Background. A prospective trial was conducted to confirm the diagnostic performance of 123I-mIBG scintigraphy in patients with known or suspected neuroblastoma. Procedure. One hundred patients (mean age 4.7 years) were enrolled, 86 with a previous diagnosis of neuroblastoma, 13 with suspected disease based upon symptoms, imaging findings, and elevated catecholamines, and one adult with an abdominal tumor thought to be of neuroendocrine origin. All patients underwent whole-body planar imaging 24 hr following IV administration of 1-10 mCi (37-370 MBq) 123I-mIBG. SPECT imaging of the thorax/abdomen/pelvis was performed in 51 patients. Images were interpreted by three blinded readers, with consensus requiring agreement of at least two readers. Disease status was confirmed by histopathology, imaging results, catecholamine measurements, and follow-up. Results. Sixty-four patients had active disease, 30 were without disease, and 6 were judged indeterminate because of insufficient confirmatory data. 123I-mIBG scintigraphy had a sensitivity of 88% (56/64) and specificity of 83% (25/30). Sensitivity was 91% (30/33) among the subset of subjects who had both planar and SPECT imaging. Among 53 patients with recent histopathology, sensitivity and specificity were 93% and 92%, respectively. Most false-negative interpretations were in patients with minimal residual disease (n=4), while false-positive interpretations generally involved atypical adrenal or other physiological uptake (n=4). Conclusions. This prospective multicenter trial of 123I-mIBG scintigraphy documents high sensitivity and specificity of this imaging technique in patients with both newly diagnosed and previously treated neuroblastoma.

Original languageEnglish
Pages (from-to)784-790
Number of pages7
JournalPediatric Blood and Cancer
Volume52
Issue number7
DOIs
StatePublished - Jul 1 2009

Fingerprint

Neuroblastoma
Radionuclide Imaging
Multicenter Studies
Single-Photon Emission-Computed Tomography
Catecholamines
Whole Body Imaging
Sensitivity and Specificity
Residual Neoplasm
Pelvis
Abdomen
Thorax
Neoplasms

Keywords

  • Iodine-123
  • mIBG
  • Neuroblastoma
  • Scintigraphy

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

123I-mIBG scintigraphy in patients with known or suspected neuroblastoma : Results from a prospective multicenter trial. / Vik, Terry; Pfluger, Thomas; Kadota, Richard; Castel, Victoria; Tulchinsky, Mark; Farto, J. C Alonso; Heiba, Sherif; Serafini, Aldo; Tumeh, Sabah; Khutoryansky, Natalie; Jacobson, Arnold F.

In: Pediatric Blood and Cancer, Vol. 52, No. 7, 01.07.2009, p. 784-790.

Research output: Contribution to journalArticle

Vik, T, Pfluger, T, Kadota, R, Castel, V, Tulchinsky, M, Farto, JCA, Heiba, S, Serafini, A, Tumeh, S, Khutoryansky, N & Jacobson, AF 2009, '123I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial', Pediatric Blood and Cancer, vol. 52, no. 7, pp. 784-790. https://doi.org/10.1002/pbc.21932
Vik, Terry ; Pfluger, Thomas ; Kadota, Richard ; Castel, Victoria ; Tulchinsky, Mark ; Farto, J. C Alonso ; Heiba, Sherif ; Serafini, Aldo ; Tumeh, Sabah ; Khutoryansky, Natalie ; Jacobson, Arnold F. / 123I-mIBG scintigraphy in patients with known or suspected neuroblastoma : Results from a prospective multicenter trial. In: Pediatric Blood and Cancer. 2009 ; Vol. 52, No. 7. pp. 784-790.
@article{116048442980476686d9618c2d50318c,
title = "123I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial",
abstract = "Background. A prospective trial was conducted to confirm the diagnostic performance of 123I-mIBG scintigraphy in patients with known or suspected neuroblastoma. Procedure. One hundred patients (mean age 4.7 years) were enrolled, 86 with a previous diagnosis of neuroblastoma, 13 with suspected disease based upon symptoms, imaging findings, and elevated catecholamines, and one adult with an abdominal tumor thought to be of neuroendocrine origin. All patients underwent whole-body planar imaging 24 hr following IV administration of 1-10 mCi (37-370 MBq) 123I-mIBG. SPECT imaging of the thorax/abdomen/pelvis was performed in 51 patients. Images were interpreted by three blinded readers, with consensus requiring agreement of at least two readers. Disease status was confirmed by histopathology, imaging results, catecholamine measurements, and follow-up. Results. Sixty-four patients had active disease, 30 were without disease, and 6 were judged indeterminate because of insufficient confirmatory data. 123I-mIBG scintigraphy had a sensitivity of 88{\%} (56/64) and specificity of 83{\%} (25/30). Sensitivity was 91{\%} (30/33) among the subset of subjects who had both planar and SPECT imaging. Among 53 patients with recent histopathology, sensitivity and specificity were 93{\%} and 92{\%}, respectively. Most false-negative interpretations were in patients with minimal residual disease (n=4), while false-positive interpretations generally involved atypical adrenal or other physiological uptake (n=4). Conclusions. This prospective multicenter trial of 123I-mIBG scintigraphy documents high sensitivity and specificity of this imaging technique in patients with both newly diagnosed and previously treated neuroblastoma.",
keywords = "Iodine-123, mIBG, Neuroblastoma, Scintigraphy",
author = "Terry Vik and Thomas Pfluger and Richard Kadota and Victoria Castel and Mark Tulchinsky and Farto, {J. C Alonso} and Sherif Heiba and Aldo Serafini and Sabah Tumeh and Natalie Khutoryansky and Jacobson, {Arnold F.}",
year = "2009",
month = "7",
day = "1",
doi = "10.1002/pbc.21932",
language = "English",
volume = "52",
pages = "784--790",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - 123I-mIBG scintigraphy in patients with known or suspected neuroblastoma

T2 - Results from a prospective multicenter trial

AU - Vik, Terry

AU - Pfluger, Thomas

AU - Kadota, Richard

AU - Castel, Victoria

AU - Tulchinsky, Mark

AU - Farto, J. C Alonso

AU - Heiba, Sherif

AU - Serafini, Aldo

AU - Tumeh, Sabah

AU - Khutoryansky, Natalie

AU - Jacobson, Arnold F.

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Background. A prospective trial was conducted to confirm the diagnostic performance of 123I-mIBG scintigraphy in patients with known or suspected neuroblastoma. Procedure. One hundred patients (mean age 4.7 years) were enrolled, 86 with a previous diagnosis of neuroblastoma, 13 with suspected disease based upon symptoms, imaging findings, and elevated catecholamines, and one adult with an abdominal tumor thought to be of neuroendocrine origin. All patients underwent whole-body planar imaging 24 hr following IV administration of 1-10 mCi (37-370 MBq) 123I-mIBG. SPECT imaging of the thorax/abdomen/pelvis was performed in 51 patients. Images were interpreted by three blinded readers, with consensus requiring agreement of at least two readers. Disease status was confirmed by histopathology, imaging results, catecholamine measurements, and follow-up. Results. Sixty-four patients had active disease, 30 were without disease, and 6 were judged indeterminate because of insufficient confirmatory data. 123I-mIBG scintigraphy had a sensitivity of 88% (56/64) and specificity of 83% (25/30). Sensitivity was 91% (30/33) among the subset of subjects who had both planar and SPECT imaging. Among 53 patients with recent histopathology, sensitivity and specificity were 93% and 92%, respectively. Most false-negative interpretations were in patients with minimal residual disease (n=4), while false-positive interpretations generally involved atypical adrenal or other physiological uptake (n=4). Conclusions. This prospective multicenter trial of 123I-mIBG scintigraphy documents high sensitivity and specificity of this imaging technique in patients with both newly diagnosed and previously treated neuroblastoma.

AB - Background. A prospective trial was conducted to confirm the diagnostic performance of 123I-mIBG scintigraphy in patients with known or suspected neuroblastoma. Procedure. One hundred patients (mean age 4.7 years) were enrolled, 86 with a previous diagnosis of neuroblastoma, 13 with suspected disease based upon symptoms, imaging findings, and elevated catecholamines, and one adult with an abdominal tumor thought to be of neuroendocrine origin. All patients underwent whole-body planar imaging 24 hr following IV administration of 1-10 mCi (37-370 MBq) 123I-mIBG. SPECT imaging of the thorax/abdomen/pelvis was performed in 51 patients. Images were interpreted by three blinded readers, with consensus requiring agreement of at least two readers. Disease status was confirmed by histopathology, imaging results, catecholamine measurements, and follow-up. Results. Sixty-four patients had active disease, 30 were without disease, and 6 were judged indeterminate because of insufficient confirmatory data. 123I-mIBG scintigraphy had a sensitivity of 88% (56/64) and specificity of 83% (25/30). Sensitivity was 91% (30/33) among the subset of subjects who had both planar and SPECT imaging. Among 53 patients with recent histopathology, sensitivity and specificity were 93% and 92%, respectively. Most false-negative interpretations were in patients with minimal residual disease (n=4), while false-positive interpretations generally involved atypical adrenal or other physiological uptake (n=4). Conclusions. This prospective multicenter trial of 123I-mIBG scintigraphy documents high sensitivity and specificity of this imaging technique in patients with both newly diagnosed and previously treated neuroblastoma.

KW - Iodine-123

KW - mIBG

KW - Neuroblastoma

KW - Scintigraphy

UR - http://www.scopus.com/inward/record.url?scp=67650481556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650481556&partnerID=8YFLogxK

U2 - 10.1002/pbc.21932

DO - 10.1002/pbc.21932

M3 - Article

VL - 52

SP - 784

EP - 790

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 7

ER -